Join
Live feed
·
PRReleasevia Quantisnow
Actinium Pharmaceuticals Inc. (Delaware) logo

Actinium Pharmaceuticals Highlights Antibody Radiation Conjugate Program Developments and Reports Financial Results for the Third Quarter 2024

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ATNM (Actinium Pharmaceuticals Inc. (Delaware)) and more on Quantisnow.